Eli Lilly (LLY.N) announced on Monday 6th that it plans to invest more than $1 billion in India over the coming years to strengthen its manufacturing capabilities and supply chain through collaborations with local drugmakers. The initiative is part of the company’s broader strategy to leverage India’s skilled workforce to support its global manufacturing expansion.
The partnerships with Indian pharmaceutical companies aim to enhance the availability of Lilly’s key therapies, covering a range of critical health areas, including:
-
Obesity
-
Diabetes
-
Alzheimer’s disease
-
Cancer
-
Autoimmune conditions
According to the company, the investments will not only support production and supply but also foster local innovation and manufacturing expertise, ensuring that high-quality medicines are delivered efficiently to patients globally.
This move underscores India’s growing role in the global pharmaceutical supply chain, positioning the country as a strategic hub for both manufacturing and distribution of complex therapies.